Biotechnology

Eye
#Biotechnology #Clinical trials #Drug development #Drug discovery #Stem cells

Dry Eye Syndrome drug candidate shows promise

BRIM Biotechnology has announced it is preparing to initiate Phase III trials in 2022 for BRIM421. BRIM421 is a first-in-class peptide derived from BRIM’s proprietary, stem cell regenerative, Short Peptide (PDSP) technology platform, which can also be applied across multiple therapy areas and indications. Data demonstrate the drug has the… Read More

#News

Scotland
#Bioeconomics #Biosciences #Biotechnology

Scottish fund supports biotechnology spin-outs

The Industrial Biotechnology Innovation Centre (IBioIC) has launched a Spin-Out Support Programme to provide funding for the commercialisation of industrial biotechnology concepts and the creation of spin-outs, helping drive the growth of Scotland’s bioeconomy. Funding will support researchers at Scottish universities to progress bio-based research and establish new companies, within… Read More

#News

#Biotechnology #Clinical trials #Data

Formedix and CDISC join forces to accelerate clinical trial set-up

Formedix, a provider of clinical trial software solutions, has collaborated with CDISC, the global clinical research data standards development organisation, to create a novel portal providing free access to ready-to-use, CDASH-compliant, annotated electronic case report forms (eCRFs). As part of this partnership, Formedix’s all-in-one cloud-based clinical metadata repository (CMDR) and… Read More

#News

#Biology #Biotechnology #Drug development #Drug discovery #Life sciences #SLAS 2021

Poster award deadlines approaching for SLAS 2021

The deadlines for the Tony B. Academic Award and the Student Poster Award for SLAS Europe 2021 is June 14, a week prior to the conference, which takes place June 23-25 digitally. SLAS’ call for poster abstracts provide opportunities to receive recognition, experience and praise for original research by a… Read More

#News

#Biotechnology #Drug discovery #High throughput screening #Whitepaper

High-throughput screening for small molecule drug discovery

High-throughput screening remains one of the most powerful, unbiased approaches for small molecule drug discovery. In this whitepaper, “Disrupting Drug Discovery From Assay Development to Lead Compound”, SAMDI Tech CSO, Zack Gurard-Levin, discusses the important aspects to consider when choosing the right methodology for drug discovery. The whitepaper covers traditional… Read More

#News

#Biotechnology #Drug screening

Berkeley Lights releases subscription-based access program

Berkeley Lights has released its TechAccess Subscription model to enable broader customer access to their single-cell screening technology. The new offering brings requested volume and throughput flexibility to customers who want to access the company’s cell line development and antibody discovery workflows. The all-inclusive subscription provides customers with a comprehensive… Read More

#News

#Biotechnology #Biotherapeutics #Drug delivery

Collaboration to develop new therapeutic drug conjugates

Aptamer and PinotBio have entered into a strategic collaboration agreement to develop Optimer-drug conjugates for targeted drug delivery, combining Aptamer’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker. Optimer therapeutics are optimised aptamer solutions. Optimer-drug conjugates offer uniquely specific targeting vehicles for the delivery of… Read More

#News

#Biotechnology #Diagnostics #Drug discovery #Immunology #Immunology / Virology & Vaccines #Pandemic

University of Oxford to launch Pandemic Sciences Centre

The University of Oxford has announced the launch of a new centre of global research collaboration and excellence, the Pandemic Sciences Centre. Its mission will be to ensure that the world is better equipped to create global, and equitable science-driven solutions to prepare for, identify, and counter future pandemic threats. Read More

#News #Trending News

#3D modelling #Biopharmaceuticals #Biotechnology #Drug screening #Drug targets

Optibrium and BioPharmics computational drug design partnership

The first outcome of the Optibrium and BioPharmics collaboration will be a new module for StarDrop, Optibrium’s small molecule design, optimisation and analysis software,. The new Surflex eSim 3D module, planned for the third quarter of 2021, will leverage BioPharmics’ three-dimensional (3D) ligand-based design approaches, offering exceptional virtual screening and… Read More

#News

#3D modelling #Antibiotics #Biotechnology #Cell / tissue culture #Data #Drug discovery #Drug targets #Drug technology #Imaging

How imaging techniques are innovating drug discovery

Lu Rahman takes look at some of the latest imaging innovation available and how it can benefit drug target identification and drug discovery research. Imaging is an important element within the drug discovery and development process providing researchers with information that can help identify potential drug targets or see how… Read More

#Exclusive Content #News #Trends & Analysis

#Biopharmaceuticals #Biotechnology #Drug development #Novel therapeutics

PerkinElmer acquires Nexcelom Bioscience

PerkinElmer has entered into an agreement to acquire Nexcelom Bioscience for US$260 million. The transaction is expected to close during the second quarter of 2021. Nexcelom provides automated cell counting instruments and aids in the development of cell and gene and immuno-oncology therapies, virology drugs and vaccines. Its expected 2021… Read More

#News

#Biotechnology #Data #Research

Vizgen advances spatial genomics research

Vizgen has released its first freely available dataset, the Vizgen MERFISH Mouse Brain Receptor Map. This is reportedly the first of a series of datasets that will be made available through the company’s new Data Release Program. The MERFISH release is said to mark the first time the research community… Read More

#News

#Biotechnology #Drug development #FDA #Research

The FDA expands lung-on-a-chip collaboration with CN Bio

The US. Food and Drug Administration (FDA) has extended its research collaboration with CN Bio for a further three years. The scope of the research carried out with the FDA’s Center for Drug Evaluation and Research (CDER) has now been broadened to include the exploration of CN Bio’s lung-on-a-chip using… Read More

#News

#Biotechnology #Cell and gene therapy #Covid-19 #Drug delivery #Drug development #Drug technology #Immunology / Virology & Vaccines

Antibody therapeutics: the other race for immunity against SARS-CoV2

Sophie Lutter, OXGENE, looks at the important role antibody therapeutics have to play and how, as the world has looked for Covid-19 treatments in the last year, their significance has been noted. As the world continues to adjust and respond to the impact of the Covid-19 pandemic, the race to… Read More

#Covid-19 #Exclusive Content #News

#Big pharma #Biotechnology #Pharmaceuticals

Sygnature Discovery expands US presence to Bay Area biotech hub

Sygnature Discovery, an integrated discovery and pre-clinical solutions provider, has a new office in South San Francisco’s biotech hub at Oyster Point, where it says it can better serve current and future clients on the US west coast. The company has grown in the previous year, having recently expanded… Read More

#News

#Biotechnology #Cell and gene therapy #Cell therapy #Genetics

Partnership to advance diversified gene therapy pipeline

Gene therapy company AavantiBio and Catalent, technologies, development, and manufacturing solutions service, have partnered to support the development and manufacturing of AavantiBio’s gene therapies, including Friedreich’s Ataxia (FA). Catalent will provide process development and CGMP manufacturing of AavantiBio’s adeno-associated viral (AAV) vector-based therapeutic candidate for use in clinical trials in the… Read More

#News